R3918-MG-2018
Brief description of study
This protocol is to see the affects of different combination therapy of Pozelimab and Cemdisiran in patient's with Symptomatic generalized myasthenia gravis. The study is split into 5 different parts: Screening. randomization and double blind study treatment period, double blind extension study treatment period, open-label study treatment period, and follow up period.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
